This segment focuses on the discovery and development of novel antiviral therapeutics targeting serious and chronic viral diseases. Cocrystal Pharma employs structure-based technologies to design and optimize antiviral drug candidates. Research and development activities include preclinical studies, clinical trials, and collaborations with research institutions and pharmaceutical companies. The company's pipeline includes drug candidates targeting hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The goal is to develop effective and safe antiviral treatments that address unmet medical needs and improve patient outcomes. This segment leverages partnerships with organizations like Merck Sharp & Dohme Corp. and Kansas State University Research Foundation to expand its research capabilities and accelerate drug development.

Cocrystal Pharma is actively engaged in the development of influenza A/B antiviral agents, including CC-42344, a PB2 inhibitor currently in preclinical development. This segment focuses on creating innovative treatments that target the replication machinery of influenza viruses. The company's research involves identifying and developing non-nucleoside polymerase inhibitors to combat influenza infections. By collaborating with Merck Sharp & Dohme Corp., Cocrystal Pharma aims to discover and develop proprietary influenza A/B antiviral agents with improved efficacy and safety profiles. The ultimate goal is to provide effective therapeutic options for patients suffering from influenza, reducing the severity and duration of the illness and preventing potential complications.

This segment is dedicated to identifying and developing non-nucleoside polymerase inhibitors for norovirus and coronavirus infections. Cocrystal Pharma is leveraging its structure-based drug design expertise to create antiviral compounds that target the replication process of these viruses. The company has a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Research and development efforts are focused on preclinical studies and lead optimization to identify promising drug candidates for clinical development. The goal is to develop effective treatments for norovirus and coronavirus infections, addressing the significant public health burden caused by these viruses.